191 related articles for article (PubMed ID: 7666816)
41. Effects of transdermal 17 beta-oestradiol combined with oral progestogen on lipids and lipoproteins in hypercholesterolaemic postmenopausal women.
Słowińska-Srzednicka J; Zgliczyński S; Chotkowska E; Srzednicki M; Stopińska-Głuszak U; Jeske W; Brzezińska A; Zgliczyński W; Sadowski Z
J Intern Med; 1993 Nov; 234(5):447-51. PubMed ID: 7693846
[TBL] [Abstract][Full Text] [Related]
42. The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins.
Bhathena RK; Anklesaria BS; Ganatra AM; Pinto R
Br J Clin Pharmacol; 1998 Feb; 45(2):170-2. PubMed ID: 9491833
[TBL] [Abstract][Full Text] [Related]
43. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
44. Plasma lipoproteins and fatty acid composition after "minipill".
Sassolas A; Lagarde M; Guichardant M; Quincy C; Dechavanne M
Contraception; 1983 Oct; 28(4):357-68. PubMed ID: 6421540
[TBL] [Abstract][Full Text] [Related]
45. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
Hirvonen E; Mälkönen M; Manninen V
N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
[TBL] [Abstract][Full Text] [Related]
46. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen.
Wilson ES; Cruickshank J; McMaster M; Weir RJ
Br J Obstet Gynaecol; 1984 Dec; 91(12):1254-60. PubMed ID: 6440589
[TBL] [Abstract][Full Text] [Related]
47. Effect of norethisterone and levonorgestrel in low-dose multiphasic oral contraceptives on serum lipids.
Wiik P; Nordby J; Paulsen JE
Acta Obstet Gynecol Scand; 1993 Oct; 72(7):550-5. PubMed ID: 8213103
[TBL] [Abstract][Full Text] [Related]
48. A study on the effects of Norplant implantable contraceptive on lipid, lipoprotein, and apolipoprotein metabolism in Singaporean women.
Singh K; Ratnam SS
Contraception; 1997 Aug; 56(2):77-83. PubMed ID: 9315415
[TBL] [Abstract][Full Text] [Related]
49. Oral versus transdermal hormone replacement therapy.
Stevenson JC; Crook D; Godsland IF; Lees B; Whitehead MI
Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():30-5. PubMed ID: 8499957
[TBL] [Abstract][Full Text] [Related]
50. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.
Tilly-Kiesi M; Kahri J; Pyörälä T; Puolakka J; Luotola H; Lappi M; Lahdenperä S; Taskinen MR
Atherosclerosis; 1997 Mar; 129(2):249-59. PubMed ID: 9105568
[TBL] [Abstract][Full Text] [Related]
51. Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women.
Adami S; Rossini M; Zamberlan N; Bertoldo F; Dorizzi R; Lo Cascio V
Maturitas; 1993 Nov; 17(3):191-6. PubMed ID: 8133793
[TBL] [Abstract][Full Text] [Related]
52. National differences in lipid response to postmenopausal hormone replacement therapy.
Ranta V; Oksanen H; Arrenbrecht S; Ylikorkala O
Maturitas; 2002 Aug; 42(4):259-65. PubMed ID: 12191848
[TBL] [Abstract][Full Text] [Related]
53. Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides.
Nerbrand C; Nyberg P; Nordström L; Samsioe G
Maturitas; 2002 May; 42(1):55-62. PubMed ID: 12020980
[TBL] [Abstract][Full Text] [Related]
54. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.
Haarbo J; Hassager C; Jensen SB; Riis BJ; Christiansen C
Am J Med; 1991 May; 90(5):584-9. PubMed ID: 1827568
[TBL] [Abstract][Full Text] [Related]
55. Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT.
Boon J; Scholten PC; Oldenhave A; Heintz AP
Maturitas; 2003 Sep; 46(1):69-77. PubMed ID: 12963171
[TBL] [Abstract][Full Text] [Related]
56. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
57. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
Sivin I; Stern J; Diaz S; Pavéz M; Alvarez F; Brache V; Mishell DR; Lacarra M; McCarthy T; Holma P
Am J Obstet Gynecol; 1992 Apr; 166(4):1208-13. PubMed ID: 1566771
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of a new triphasic oral contraceptive in private practice.
Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
[TBL] [Abstract][Full Text] [Related]
59. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
Luukkainen T; Toivonen J
Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
[TBL] [Abstract][Full Text] [Related]
60. Effects of Mirena (levonorgestrel-releasing intrauterine system) and Ortho Gynae T380 intrauterine copper device on lipid metabolism--a randomized comparative study.
Ng YW; Liang S; Singh K
Contraception; 2009 Jan; 79(1):24-8. PubMed ID: 19041437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
